Hormonal
GZR18, a GLP-1 receptor agonist administered once-weekly or bi-weekly, induces robust body weight reductions (up to 17.8%) and improves metabolic parameters in Chinese adults with overweight or obesity.
GZR18 is a once-weekly or bi-weekly GLP-1 injection that helps overweight or obese Chinese adults lose significant weight (up to 17.8%) and improve metabolic health. It is designed to minimize side effects like nausea, making it a potentially tolerable option for those who struggle with frequent injections or severe gastrointestinal issues from other GLP-1 drugs. Consult a doctor to see if it's appropriate for you.
In Chinese adults with overweight/obesity, GZR18 induces robust weight reductions (up to -17.8%) and is generally safe and well tolerated.
Why this rating
Phase 1b/2a randomized, placebo-controlled trial with a relatively small sample size (N=60) and short duration (26-35 weeks).
Source
GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial
Linong Ji et al. · Cell Reports Medicine · 2026
DOI 10.1016/j.xcrm.2026.102743
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →